Adagrasib
Adagrasib (INN, codenamed MRTX-849), is an experimental cancer drug being developed by Mirati Therapeutics. It acts as a covalently binding inhibitor for a mutant form of the protein KRAS called G12C, which is commonly present in various forms of cancer and acts as a growth factor. It has shown promising results in pre-clinical testing and is currently in clinical trials.[1][2][3][4][5][6]
Clinical data | |
---|---|
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
DrugBank | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C32H35ClFN7O2 |
Molar mass | 604.13 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
|
See also
References
- Hallin J, Engstrom LD, Hargis L, Calinisan A, Aranda R, Briere DM, et al. (January 2020). "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients". Cancer Discovery. 10 (1): 54–71. doi:10.1158/2159-8290.CD-19-1167. PMC 6954325. PMID 31658955.
- Fell JB, Fischer JP, Baer BR, Blake JF, Bouhana K, Briere DM, et al. (July 2020). "Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer". Journal of Medicinal Chemistry. 63 (13): 6679–6693. doi:10.1021/acs.jmedchem.9b02052. PMID 32250617.
- Thein KZ, Biter AB, Hong DS (January 2021). "Therapeutics Targeting Mutant KRAS". Annual Review of Medicine. 72: 349–364. doi:10.1146/annurev-med-080819-033145. PMID 33138715.
- Christensen JG, Olson P, Briere T, Wiel C, Bergo MO (August 2020). "Targeting Krasg12c -mutant cancer with a mutation-specific inhibitor". Journal of Internal Medicine. 288 (2): 183–191. doi:10.1111/joim.13057. PMID 32176377.
- Dunnett-Kane V, Nicola P, Blackhall F, Lindsay C (January 2021). "Mechanisms of Resistance to KRASG12C Inhibitors". Cancers. 13 (1). doi:10.3390/cancers13010151. PMC 7795113. PMID 33466360.
- Jänne, Pasi A.; Riely, Gregory J.; Gadgeel, Shirish M.; Heist, Rebecca S.; Ou, Sai-Hong I.; Pacheco, Jose M.; Johnson, Melissa L.; Sabari, Joshua K.; Leventakos, Konstantinos; Yau, Edwin; Bazhenova, Lyudmila; Negrao, Marcelo V.; Pennell, Nathan A.; Zhang, Jun; Anderes, Kenna (2022-07-14). "Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRASG12C Mutation". New England Journal of Medicine. 387 (2): 120–131. doi:10.1056/NEJMoa2204619. ISSN 0028-4793. PMID 35658005.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.